A Victory for Safety

Common sense finally won last week when President Bush's pick to head the Consumer Product Safety Commission, Michael Baroody, withdrew his nomination. As you recall, Mr. Baroody was Executive Vice President at the National Association of Manufacturers (NAM) - a K Street lobbying behemoth devoted to helping big manufacturers evade accountability for their wrongdoing.

Comments

Post a Comment

Popular posts from this blog

Government Report Details CHI St. Luke's Hospital Lack of Infection Prevention

Image
Damning Government Investigation and Report Details Serious Safety Lapses at CHI St. Luke’s, Houston, Texas Patients received medications that weren’t ordered by doctors; objects were mistakenly left in patients after surgery; and ultrasound probes were reused without being property disinfected, government inspectors found. The hospital says it is fixing the problems. https://www.propublica.org/…/st-lukes-in-houston-blistering… Yuck, cleaning a transvaginal transducer with tap water and paper towels??! Sad, St. Luke's used to be a respected hospital. In an interview conducted on 3/27/19 at 10:10 am, Staff#122 was asked by the surveyor how she was disinfecting the transvaginal transducers.  She stated, "I just run them under the tap water and wipe them off with a paper towel."
Read more

Certain Zicam Class Actions Settled

Zicam-maker Matrixx Initiatives agreed to settle certain Zicam class actions related to false advertising and warnings. Zicam has agreed to add warning labels to their products should the FDA allow the return of zinc-containing Zicam products to the market. We are pleased that Matrixx has taken this first step to resolving this litigation and continue to work hard to resolved the personal injury lawsuits.
Read more

FDA: Multaq and Liver Failure

According to an FDA Safety Announcement, the potential side effects of Multaq, a prescription drug used to treat abnormal heart rhythm, may be linked to an increased risk of acute liver failure or other liver problems. See the FDA WARNING: Severe Liver Injury with Multaq Multaq (dronedaron) is a new medication that was just approved in July 2009. It is used to treat patients who have had an abnormal heart rhythm during the past six months, such as atrial fibrillation or atrial flutter. Although it has only been on the market for a short period of time, nearly 150,000 people in the United States filled a prescription for the heart drug as of October 2010. The FDA has received a number of reports of heptocellular liver injury and hepatic failure among users of Multaq, including at least two cases of acute liver failure from Multaq that resulted in the need for a liver transplant. The two cases of Multaq liver failure occurred within the first six mon...
Read more